05:56:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-25 X-dag ordinarie utdelning MEDI 4.50 NOK
2024-04-24 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-25 Kvartalsrapport 2023-Q1
2023-04-25 X-dag ordinarie utdelning MEDI 4.50 NOK
2023-04-24 Årsstämma 2023
2023-03-01 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 X-dag ordinarie utdelning MEDI 3.75 NOK
2022-04-27 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-10-22 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-04-28 X-dag ordinarie utdelning MEDI 3.00 NOK
2021-04-27 Kvartalsrapport 2021-Q1
2021-04-27 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-10-22 X-dag ordinarie utdelning MEDI 2.75 NOK
2020-08-14 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-04-28 Årsstämma 2020
2020-04-03 Extra Bolagsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-04-25 X-dag ordinarie utdelning MEDI 2.25 NOK
2019-04-25 Kvartalsrapport 2019-Q1
2019-04-24 Årsstämma 2019
2019-03-15 Bokslutskommuniké 2018
2019-02-27 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-04-26 X-dag ordinarie utdelning MEDI 2.00 NOK
2018-04-26 Kvartalsrapport 2018-Q1
2018-04-25 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-27 X-dag ordinarie utdelning MEDI 1.75 NOK
2017-04-27 Kvartalsrapport 2017-Q1
2017-04-26 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-10-19 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-04-20 X-dag ordinarie utdelning MEDI 1.65 NOK
2016-04-19 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-04-24 X-dag ordinarie utdelning MEDI 1.40 NOK
2015-04-24 Kvartalsrapport 2015-Q1
2015-04-23 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-04-25 Kvartalsrapport 2014-Q1
2014-04-24 X-dag ordinarie utdelning
2014-04-23 Årsstämma 2014
2014-02-20 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-20 Kvartalsrapport 2013-Q2
2013-04-26 X-dag ordinarie utdelning
2013-04-25 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-08 Kapitalmarknadsdag 2013
2013-02-28 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-04-27 Kvartalsrapport 2012-Q1
2012-04-27 X-dag ordinarie utdelning
2012-04-26 Årsstämma 2012
2012-02-22 Bokslutskommuniké 2011
2011-10-28 Kvartalsrapport 2011-Q3
2011-08-24 Kvartalsrapport 2011-Q2
2011-04-29 X-dag ordinarie utdelning
2011-04-29 Kvartalsrapport 2011-Q1
2011-04-28 Årsstämma 2011
2011-02-18 Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Medistim är ett ultraljudsteknikföretag. Medistim utvecklar och kommersialiserar medicinsk utrustning för användning inom hjärt-, kärl- och transplantationskirurgi. Företaget strävar efter att minska risker och förbättra kvaliteten i sådana operationer genom att använda överföringstidsflödesmätning och högfrekvent ultraljudsavbildning. Medistim har dotterbolag och distributörer med försäljningsorganisationer på marknader runt om i världen. Kunderna är offentliga och privata sjukhus och företaget har sitt huvudkontor i Norge.
2023-06-05 08:30:00
(Oslo, June 5, 2023) Medistim ASA (OSE: MEDI), a global niche market leader in
ultrasound technology for medical use in Cardiac, Vascular and Transplant
surgery, is pleased to announce its partnership with ROMA-Women, a
groundbreaking cardiac surgery trial that is specifically focused on women.
Historically, cardiovascular research and treatment protocols have primarily
focused on men, leaving women underrepresented in clinical studies and
potentially receiving suboptimal care. Recognizing this disparity, Medistim has
joined forces with the trial to champion gender-specific healthcare
advancements.

The multicenter randomized clinical trial, ROMA-Women, will enroll about 2,000
women, studying the use of single versus multiple arterial grafts in coronary
artery bypass (CABG) surgery. The trial is spearheaded by renowned experts in
the field of cardiac surgery, including principal investigators Mario Gaudino,
Professor at Weill Cornell Medicine, USA, and Stephen Fremes, Professor at
Sunnybrook Health Sciences, Canada. More than 100 centers across the world are
expected to participate. The trial is an extension of the ongoing ROMA trial
and has already enrolled about 700 women.

ROMA-Women aims to address the unique cardiovascular needs and challenges faced
by women. Compared to men, women are referred for CABG at an older age and have
more frequently diabetes, hypertension, and dyslipidemia. From a surgical
perspective, the CABG operation is generally more complex in women because of
smaller and more spastic coronary arteries than men. Hence, it is believed that
graft assessment may be even more important in women, and in this trial, graft
patency will be assessed with Medistim's Transit Time Flow Measurement (TTFM)
and High Frequency Ultrasound (HFUS) technologies.

"We are thrilled to collaborate with this pioneering cardiac surgery trial
exclusively dedicated to women," says Kari E. Krogstad, President and CEO at
Medistim. "In this trial, we will contribute with our expertise, resources, and
innovative technologies. At Medistim, we are passionate about advancing patient
care and empowering women in all parts of the patient care value chain. This
partnership not only aligns with our company culture but also embodies our
commitment to driving innovation and addressing the unmet needs of diverse
patient populations."

"We are very grateful to Medistim for the partnership and support. ROMA-Women
will not only improve women's health and outcomes after bypass surgery, but also
has the potential to revolutionize the approach to generating evidence in women
and patients who have traditionally not been adequately represented in clinical
trials. This is an enormous and ambitious effort, and we need all the help
possible - Medistim stepping in and being at our side is instrumental in the
success of the trial," says lead investigator Mario Gaudino.

About Medistim: Medistim is a pioneering MedTech company dedicated to improving
patient outcomes through innovation and advanced technology. With a deep-rooted
commitment to delivering patient-centered care, Medistim is transforming the
landscape by developing tailored solutions for diverse applications. Medistim
was established in 1984 and has a track record of profitable growth over the
past 20 years. Medistim has wholly owned subsidiaries with sales organizations
in the USA, Canada, China, Germany, the UK, Spain, Denmark, and Norway, in
addition to around 60 distributors in Europe, Asia, the Middle East, Africa, and
South America.


For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com